Ann Hematol:胸腺MALT淋巴瘤的分子遗传学和临床病理特征

2021-10-08 MedSci原创 MedSci原创

导致NF-κB通路激活的分子畸变参与了胸腺MALT淋巴瘤的发病机制,涉及NF-κ b通路的分子畸变在胸腺MALT淋巴瘤中很常见,CCND3突变提示PI3K通路失调可能也参与了胸腺MALT淋巴瘤的发病机

粘膜相关淋巴样组织的结外边缘区b细胞淋巴瘤 (MALT) 是一种低度恶性b细胞淋巴瘤。胸腺MALT淋巴瘤的临床病理特征由于该疾病的罕见性仍然较差。到目前为止,还没有研究探索胸腺MALT淋巴瘤的分子特征。目前尚不清楚胸腺MALT淋巴瘤是否具有类似于其他解剖部位的MALT淋巴瘤的突变景观。

国外一研究团队调查了来自单一中心的11例胸腺MALT淋巴瘤的临床病理特征。此外,对有可用样本的患者进行了靶向基因测序。这项研究的目的是研究胸腺MALT淋巴瘤的临床病理特征。还对相关文献进行了回顾。

11例患者的中位年龄为50岁 (range33-60)。女性占主导地位,男女比例为101。3例患者分别出现干燥综合征,自身免疫性血小板减少性紫癜和B1型胸腺瘤。显微镜下,胸腺MALT淋巴瘤的特征是上皮衬里的囊肿,周围是小淋巴细胞,中心细胞样细胞和单核细胞样b细胞。在两例病例中观察到浆细胞分化。肿瘤细胞表达CD20,CD79α 和bcl2。在所有8例检查病例中均检测到克隆免疫球蛋白基因。7例进行了18q21的荧光原位杂交 (FISH),未发现涉及18q21的易位。在5例有可用DNA样本的病例中进行了靶向基因测序,并鉴定出TNFAIP3,CARD11,IGLL5和CCND3突变。

研究表明,导致NF-κB通路激活的分子畸变参与了胸腺MALT淋巴瘤的发病机制,涉及NF-κ b通路的分子畸变在胸腺MALT淋巴瘤中很常见,CCND3突变提示PI3K通路失调可能也参与了胸腺MALT淋巴瘤的发病机制。由于使用的是靶向基因测序,没有检测到不包含在当前面板中的基因发生的突变。由于涉及其他基因的突变也可能有助于胸腺MALT淋巴瘤的发展,需要全外显子组测序,以更好地防御胸腺MALT淋巴瘤的遗传景观。未来使用RNA测序或全基因组测序来检测致病性染色体易位也很重要。

 

原始出处:

Wang, X., Miao, Y., Cao, Z. et al. Characterization of molecular genetics and clinicopathology in thymic MALT lymphoma. Ann Hematol (2021). https://doi.org/10.1007/s00277-021-04671-0

评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2022-06-25 shizhenshan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1663511, encodeId=b57b166351123, content=<a href='/topic/show?id=451a8418304' target=_blank style='color:#2F92EE;'>#胸腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84183, encryptionId=451a8418304, topicName=胸腺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcbd25619530, createdName=1508842480_96220445, createdTime=Tue Oct 12 10:52:51 CST 2021, time=2021-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861474, encodeId=2f5a18614e4e9, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Sat Jun 25 02:52:51 CST 2022, time=2022-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1844003, encodeId=4f1b1844003d9, content=<a href='/topic/show?id=05e29508559' target=_blank style='color:#2F92EE;'>#遗传学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95085, encryptionId=05e29508559, topicName=遗传学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sun Nov 07 20:52:51 CST 2021, time=2021-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033210, encodeId=9559203321096, content=<a href='/topic/show?id=c097e104497' target=_blank style='color:#2F92EE;'>#病理特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71044, encryptionId=c097e104497, topicName=病理特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Fri Jun 17 00:52:51 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797488, encodeId=28e61e97488ea, content=<a href='/topic/show?id=96eb22906b9' target=_blank style='color:#2F92EE;'>#临床病理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22906, encryptionId=96eb22906b9, topicName=临床病理)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 12 05:52:51 CST 2022, time=2022-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317657, encodeId=6832131e657b6, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Sun Oct 10 04:52:51 CST 2021, time=2021-10-10, status=1, ipAttribution=)]
    2021-10-10 柳叶一刀

相关资讯

Ⅲ期胃癌患者应尽可能施行R0根治术

  近日,中国医科大学附属第一医院胃肠肿瘤外科徐岩、孙哲、王振宁等人发表论文,旨在探讨Ⅲ期胃癌(按第7版TNM分期标准)的临床病理特征及影响预后的相关因素。研究指出,Ⅲ期胃癌患者有其自身的临床病理学特点,治疗上应尽可能施行R0根治术。淋巴结转移数目、肿瘤浸润深度和Borrmann分型是影响接受R0手术的Ⅲ期胃癌患者预后的重要因素。该文发表在2012年第15卷第2期《中华胃肠外科杂志》上。   回

SCI REP:胃腺鳞癌的临床病理特征及预后!

由此可见,胃部ASC与AC在临床病理特征上具有明显的不同,并且胃部ASC的预后要明显差于AC。

拓展阅读

淋巴瘤疑难病例线上诊疗交流会

淋巴瘤疑难病例 线上诊疗交流会

【CBM】钱文斌/张会来教授等总结提高CAR-T淋巴瘤疗效的策略

本文综述了近年来为提高CAR-T细胞疗法在淋巴瘤治疗中的疗效所采取的多项策略,包括改进抗原识别、抑制免疫检查点信号、增强杀伤能力、提高安全性以及代谢和表观遗传调控等方面的创新方法。

淋巴瘤中循环肿瘤DNA的检测技术及应用

ctDNA 为 cfDNA 子集,可作淋巴瘤无创诊断等生物标志物。本文介绍淋巴瘤分子遗传特征、ctDNA 检测方法及在各亚型应用,指其机遇与挑战,助推进个性化医疗。

【衡道丨干货】2025 中国肿瘤整合诊治指南(CACA) ——淋巴瘤

《2025 中国肿瘤整合诊治指南(CACA)——淋巴瘤》详细介绍了淋巴瘤的诊疗总则、病理分类、活检与制片、组织病理学检查、流式细胞术分析、遗传学与分子病理检测等内容。

3期淋巴瘤试验中肿瘤“大包块(bulk)”的定义和使用需要统一

学者开展综合性文献综述。评估了四种主要淋巴瘤亚型的3期随机试验中大包块的定义、应用和预后影响。

中国临床肿瘤学会(CSCO)白血病、淋巴瘤及骨髓瘤专家委员会工作会议暨2025年CSCO血液肿瘤学术大会即将召开!

中国临床肿瘤学会(CSCO)白血病、淋巴瘤及骨髓瘤专家委员会工作会议暨2025年CSCO血液肿瘤学术大会将于2025年1月17日-19日在海口线下举办。

原发性中枢神经系统淋巴瘤诊断及治疗专家共识(2024年版)

中国临床肿瘤学会(CSCO,Chinese Society of Clinical Oncology) · 2024-03-25

2024 BSH指南: 大B细胞淋巴瘤的中枢神经系统预防

英国血液病学学会(BSH,British Society for Haematology) · 2024-12-12

2023 JSH实践指南:血液恶性肿瘤—淋巴瘤(概述)

日本血液学会(JSH,Japanese Society of Hematology) · 2025-03-04

中国老年淋巴瘤诊疗指南

暂未更新 · 2024-12-02

盐酸米托蒽醌脂质体注射液治疗外周T细胞淋巴瘤中国专家共识

中国抗癌协会临床肿瘤学协作专业委员会(CSCO,Chinese Society of Clinical Oncology) · 2023-12-06